A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody

What this Trial Is About

Researchers are evaluating JNJ-79635322 compared with an anti-B-cell maturation antigen BCMAxCD3 bispecific antibody in people with relapsed or refractory multiple myeloma who have received at least three prior treatments including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. This phase 3 randomized study aims to understand how well these treatments work in this patient population by comparing responses and progression outcomes over time. Participants will receive either JNJ-79635322 or teclistamab, both given as subcutaneous injections. Treatment continues until the disease progresses or side effects become intolerable. The study involves two treatment arms, one for each drug, and participants are randomly assigned to one of these groups. Both treatments are administered regularly as injections under the skin. During the study, participants will undergo various assessments including response evaluations, progression-free survival checks, and monitoring of side effects for up to five years and four months. Researchers will also track quality of life, symptom changes, and laboratory results. The study includes long-term follow-up on treatment effects, survival, and time to next therapy, with careful recording of any adverse events and immune responses to the drugs.

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma